When you have Ellansé injected, the result is often satisfying — fuller cheeks, a more defined contour. The puzzle comes when, a year or even two years later, you feel something hard at one of the original injection sites. It does not hurt, but it is firmer than skin should feel, and it stays fixed when you press it.
The first thought is usually: "Did it not absorb?" or "Will a bit of massage and heat make it go away?" — and that is exactly where delayed-onset nodules are most misunderstood. They are a different thing from the kind of firmness you feel right after the injection, and they call for a different approach.
This article is not about the decision of whether to get Ellansé in the first place. It focuses on what to do once a delayed lump has appeared: what it actually is, why it surfaces so late, why massage and blind hyaluronidase so often fail, and what we actually see — and do — in our revision practice.
1. First, tell the two apart: lumps right after injection vs. a lump a year later
Many articles describe every "Ellansé lump" as something that "absorbs on its own — just massage and apply heat." That is true for one kind and potentially misleading for the other. Clinically, the two must be separated first:
← Swipe to see more →
| Early, transient lump | Delayed-onset nodule | |
|---|---|---|
| When it appears | Days to weeks after injection | Months to one or two years after |
| Common causes | Injection technique, excess volume, too-superficial placement, early swelling | Excess collagen growth, delayed foreign-body reaction, encapsulation |
| What it is made of | Some carrier gel still present + local edema | Dense, self-produced collagen wrapping the PCL microspheres |
| Massage / heat | Sometimes helps | Usually does little |
| Self-resolution | More likely | Less likely; often needs active treatment |
Key point: Advice like "it will absorb — just massage and apply heat" targets the early, transient lump. If yours appeared long after the injection, applying the same playbook often just means waiting in vain.
2. Why does Ellansé (PCL) surface "late"? The gap between gel and microspheres
To understand a delayed nodule, look at the two components of Ellansé and what happens to each.
Ellansé is a PCL (polycaprolactone) collagen stimulator. Its contents are roughly 30% PCL microspheres suspended in about 70% CMC (carboxymethyl cellulose) carrier gel:
- The CMC carrier gel provides the "immediate fill," but it is gradually absorbed by the body within 6–8 weeks.
- The PCL microspheres are the long-acting part. They degrade slowly by hydrolysis and, depending on the product version (S / M / L / E), can persist in the tissue for about 1 to 4 years, acting as a scaffold that keeps stimulating fibroblasts to produce new collagen (which is where the name "collagen stimulator" comes from).
The problem lies in that time gap. When collagen formation is "just right," you get natural fullness. But in a minority of cases collagen growth overshoots, or the immune system mounts a delayed foreign-body reaction to the PCL microspheres after some trigger (infection, biofilm, a change in the body's status) — and the lump then surfaces at a point when the carrier gel is long gone and you thought everything had settled.
This is not a coincidence. A systematic review pooling multiple studies reported a median time to complications of about 13 months for PCL (and 18.75 months for PLLA) — in other words, "a lump more than a year later" is a fairly typical timing for PCL, not a sign that you were simply unlucky.
Key point: A late nodule does not mean you are imagining it or that "it never absorbed." The carrier gel left within 6–8 weeks; what remains and triggers a reaction a year later are the PCL microspheres still stimulating collagen.
3. Why "massage, heat, and it will absorb" does little for a delayed nodule
This is the most common misunderstanding in clinic. The advice exists because the nodule is mistaken for "filler that hasn't finished absorbing" — but the reality is the opposite.
By a year out, the carrier gel has long been metabolized; there is nothing left to "absorb." The lump you feel is mostly dense self-collagen tightly wrapping the PCL microspheres — closer to a fibrotic nodule your own body has built. Massage or heat can slightly change the surface feel and boost local circulation, but they cannot "melt" an established collagen capsule.
So if your lump:
- appeared long after the injection,
- is fixed, firm, and barely moves when pressed,
- and has shown no sign of shrinking after a period of observation,
then it is unlikely to disappear on its own with massage and heat. Spending that time "waiting a bit longer" may instead let the capsule mature and become harder to treat.
4. Hyaluronidase, steroids, 5-FU: the limits of each
Many people first think, "Can't we just dissolve it with hyaluronidase?" — and this is the most critical, most overlooked point about PCL nodules.
- Hyaluronidase: dissolves only hyaluronic acid. PCL, PLLA, PDLLA, and CaHA are collagen stimulators — none of them is hyaluronic acid, so hyaluronidase has no target in them. Injecting it into an Ellansé lump is effort aimed at the wrong substance.
- Steroids and 5-FU: these mainly suppress surrounding inflammation and excess collagen, and can sometimes soften or flatten a nodule — but they cannot remove the microsphere core itself. Repeated steroid injection also carries a risk of local skin and soft-tissue atrophy, potentially costing you tissue quality before the lump is even resolved.
- Collagenase: some recent studies have explored it for PCL nodules, but this is investigational, its efficacy and safety still need more evidence, and it must be assessed in person by a physician — it is not something to try on your own.
For balance: when injected with sound technique, PCL nodules are in fact uncommon — one retrospective study of 1,111 treatments reported no nodules or granulomas over three years of follow-up. The issue is that once a delayed nodule does form, the chemical approaches above are often not enough.
Key point: Hyaluronidase fails on Ellansé lumps not because the dose is too low, but because there is simply nothing for it to break down. Getting this straight can save you a lot of detours.
5. What we actually see in our revision practice
This section is an observation from clinical practice; placed alongside the literature above, it gives the fuller picture.
In our revision practice — which focuses on filler complications and handles a substantial volume of lump extractions every day — PCL (Ellansé) is, among the severe lumps that actually require physical extraction, a notably common and notably hard, stubborn category. In terms of our case mix, it makes up a larger share of the "hardest, most extraction-requiring" group than incidence figures alone would predict. The remaining lumps are distributed across autologous fat, hyaluronic acid, PLLA (such as Sculptra), and others — generally not as hard as PCL.
This does not contradict the literature cited above (PCL having a "low overall incidence" and the lowest granuloma rate among collagen stimulators), because the two count different denominators:
- The literature measures the proportion of complications among all injection treatments.
- Our clinic sees the material mix among severe cases referred for physical extraction.
"Low incidence" and "a high share within severe extraction cases" can both be true. The reason is intuitive: PCL persists the longest (1–4 years) of all the collagen stimulators and works through a dual "immediate fill + long-acting collagen" mechanism — so when it goes wrong, what it leaves is an encapsulated mass of residual microspheres plus dense new collagen. Physically, that is harder and more stubborn than dissolvable hyaluronic acid or softer deposits, and more likely to fall into the "hard to treat without physical extraction" end of the spectrum.
Key point: This is a single-center clinical observation, and we are the referral endpoint for severe complications, so our sample is not representative of the general population — it does not mean Ellansé has a high incidence, and it is certainly not a reason to avoid it. Most small nodules resolve on their own; the ones that genuinely need active treatment are the late, persistent lumps that clearly affect feel or appearance.
6. Ultrasound-guided "see before you treat": single-pinhole physical extraction
If the root of a delayed PCL nodule is "residual microspheres + a capsule," and chemical dissolving cannot reach it, then the logical direction is to physically remove the source — but only after you can actually see it.
Ultrasound is the key tool here. Different materials have different ultrasound signatures: hyaluronic acid appears as low-echo cystic spaces; collagen stimulators like PCL often show as punctate high-echo spots; CaHA (such as Radiesse) shows strong echoes with posterior acoustic shadowing. With ultrasound we can:
- identify which material the lump is — and whether it is an encapsulated PCL nodule;
- localize the nodule relative to nearby vessels and nerves, so dangerous structures are avoided;
- still find the residual microspheres and the extent of the capsule even years after injection.
Once the picture is clear, we physically remove it through a single, minimally invasive pinhole, addressing the source of the lump rather than repeatedly trying chemical agents. This reflects a consistent principle: you have to see it to treat it safely — no blind aspiration or blind scraping.
And the real deciding factor in extraction is often not just whether it can be removed, but whether it comes out cleanly and evenly. When technique falls short, turning one lump into a stretch of uneven dents only creates a harder problem to fix. So before extraction we map the raised areas precisely across the whole face — much as one would plan precise full-face fat grafting — taking into account the tension of facial movement and how the filler itself changes over time; then, once swelling has settled, what should come out is removed precisely, no more and no less. Dr. Ta-Ju Liu's years of experience with underarm rotary-blade surgery, liposuction with fat grafting, and liposuction-failure revision have gradually made this evenness and precision an internalized skill — and it is the difference most valued by patients who were left uneven after extraction elsewhere and came back seeking repair.
For more on whether and when PCL nodules can be removed, see the complication differences between Ellansé S / M / L versions and whether an Ellansé problem can actually be extracted. If your lumps are multiple small granules from large-area, microdroplet "skin-booster" style injection, the closer read is collagen stimulators injected like skin boosters turning into lumps.
7. What you can do after finding a delayed lump
If you are feeling a lump you suspect is a delayed Ellansé nodule, there is no need to panic — but you can start documenting it systematically, which is very useful at your consultation:
- Timeline: roughly when it was injected, which product (the version, if you know it), and roughly when the lump appeared.
- Location and change: which area, and whether it has grown, shrunk, or stayed the same over time, and whether it hurts.
- Photos: a few shots at different times under the same lighting and angle, to help judge change.
When to seek assessment early: the lump persists without resolving, is clearly hard, keeps growing, or comes with redness, warmth, or pain (the latter warrants attention for possible infection or biofilm), plus anything that affects your appearance and bothers you. Everyone's material, depth, timing, and tissue state differ, so the final approach should be decided after an in-person consultation and individualized ultrasound assessment.
For the broader context of this kind of collagen-stimulator lump, start with the causes and mechanisms of collagen stimulator lumps, the Ellansé (PCL) filler encyclopedia entry, and the collagen stimulator complications overview; for the wider topic of "lumps that appear years after injection," lumps surfacing years after filler injection covers it across materials. When you need further help, you are welcome to reach us through the filler revision clinic.
Frequently Asked Questions
Is it normal for an Ellansé lump to appear more than a year later?
"Normal" here means "not rare, and with an explainable mechanism." The PCL carrier gel is absorbed within 6–8 weeks, but the microspheres keep stimulating collagen for 1–4 years; the median onset for a delayed nodule is around 13 months post-injection, so a lump appearing more than a year later is a fairly typical timing for PCL. That said, "not rare" does not mean "ignore it" — late, persistent, firm nodules deserve an in-person assessment.
Will an Ellansé lump go away on its own?
It depends which kind. An early, transient lump in the first days-to-weeks may settle as swelling subsides or improve with massage; but a delayed-onset nodule that appears months to a year or two later is mostly dense collagen wrapping the microspheres, usually does not disappear with massage and heat, and may have a capsule that matures the longer it is left.
Can hyaluronidase dissolve an Ellansé lump?
No. Hyaluronidase only breaks down hyaluronic acid, and Ellansé is made of PCL, not hyaluronic acid, so hyaluronidase has no target in it. This is exactly why PCL nodules often need a physical approach rather than chemical dissolving.
It has been many years since the injection — can Ellansé still be removed?
In most cases, yes. Even years after injection, ultrasound can still identify and localize the residual PCL microspheres and the capsule, which can then be physically removed through a single minimally invasive pinhole. The actual feasibility and extent are confirmed after an in-person and ultrasound assessment.
Editorial Review: This article was written by Dr. Ta-Ju Liu based on current medical literature and clinical experience in filler revision, for educational purposes only; it does not constitute individual medical advice. The causes, severity, and management of Ellansé delayed-onset nodules vary from person to person — actual diagnosis and treatment should be based on an in-person and ultrasound assessment.



